Cholinergic degeneration in prodromal and early Parkinson’s disease: a link to present and future disease states
Brain · 08.01.2026 · 149 (1) · 226-237
DOI: 10.1093/brain/awaf168 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, online erschienen am 06.05.2025. Verfasst von Tamir Eisenstein und 9 weiteren Autor:innen. Beteiligte Einrichtung: Wellcome Centre for Integrative Neuroimaging, FMRIB, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford OX3 9DU, UK. Hauptthemen laut MEDLINE: Parkinson Disease, Basal Nucleus of Meynert, Cholinergic Neurons. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIHR Oxford Biomedical Research Centre, Wellcome Trust, NIHR Clinical Research Network Thames Valley and South Midlands.
Abstract (Originalsprache)
The neuropathological process in Parkinson’s disease (PD) and Lewy body disorders has been shown to extend well beyond the degeneration of the dopaminergic system, affecting other neuromodulatory systems in the brain, which play crucial roles in the clinical expression and progression of these disorders. Here, we investigate the role of the macrostructural integrity of the nucleus basalis of Meynert (NbM), the main source of cholinergic input to the cerebral cortex, in cognitive function, clinical manifestation and disease progression in non-demented subjects with PD and individuals with isolated REM sleep behaviour disorder (iRBD). Using structural MRI data from 393 early PD patients, 128 iRBD patients and 186 controls from two longitudinal cohorts, we found significantly lower NbM grey matter volume in both PD (β = −12.56, P = 0.003) and iRBD (β = −16.41, P = 0.004) compared to controls. In PD, higher NbM volume was associated with better higher-order cognitive function (β = 0.10, P = 0.045), decreased non-motor (β = −0.66, P = 0.026) and motor (β = −1.44, P = 0.023) symptom burden, and lower risk of future conversion to dementia [hazard ratio (HR) < 0.400, P < 0.004]. Higher NbM volume in iRBD was associated with decreased future risk of phenoconversion to PD or dementia with Lewy bodies (DLB) (HR < 0.490, P < 0.016). However, despite similar NbM volume deficits to those seen in PD, associations between NbM structural deficits and current disease burden or clinical state were less pronounced in iRBD. These findings identify NbM volume as a potential biomarker with dual utility: predicting cognitive decline and disease progression in early PD, while also serving as an early indicator of phenoconversion risk in prodromal disease. The presence of structural deficits before clear clinical correlates in iRBD suggests complex compensatory mechanisms may initially mask cholinergic dysfunction, with subsequent failure of these mechanisms potentially contributing to clinical conversion.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Wellcome Centre for Integrative Neuroimaging, FMRIB, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford OX3 9DU, UK.
- Oxford Parkinson's Disease Centre, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford OX3 9DU, UK.
- Department of Pharmacology & Toxicology, Faculty of Medicine, Kuwait University, Kuwait City, Kuwait.
- Population Health Sciences, Bristol Medical School, University of Bristol, Bristol BS8 2PS, UK.
- Oxford Centre for Human Brain Activity, Wellcome Centre for Integrative Neuroimaging, Department of Psychiatry, University of Oxford, Oxford OX3 7JX, UK.
ORCID-Profile: Michael A Lawton, Yoav Ben-Shlomo, Ludovica Griffanti, Michele T Hu, Johannes C Klein
Förderung
- NIHR Oxford Biomedical Research Centre
- Wellcome Trust
- NIHR Clinical Research Network Thames Valley and South Midlands
- NIHR Oxford Health Clinical Research Facility
- Parkinson's UK
- University of Oxford
- Parkinson’s UK
Zitieren
APA
Eisenstein, T., Groenewald, K., van Hillegondsberg, L., Al Hajraf, F., Zerenner, T., Lawton, M. A., Ben-Shlomo, Y., Griffanti, L., Hu, M. T., & Klein, J. C. (2026). Cholinergic degeneration in prodromal and early Parkinson’s disease: a link to present and future disease states. Brain, 149(1), 226-237. https://doi.org/10.1093/brain/awaf168
Vancouver
Eisenstein T, Groenewald K, van Hillegondsberg L, Al Hajraf F, Zerenner T, Lawton MA, et al. Cholinergic degeneration in prodromal and early Parkinson’s disease: a link to present and future disease states. Brain. 2026;149(1):226-237. doi:10.1093/brain/awaf168
BibTeX
@article{Eisenstein2026,
author = {Eisenstein, Tamir and Groenewald, Karolien and van Hillegondsberg, Ludo and Al Hajraf, Falah and Zerenner, Tanja and Lawton, Michael A and Ben-Shlomo, Yoav and Griffanti, Ludovica and Hu, Michele T and Klein, Johannes C},
title = {Cholinergic degeneration in prodromal and early Parkinson’s disease: a link to present and future disease states},
journal = {Brain},
year = {2026},
volume = {149},
number = {1},
pages = {226--237},
doi = {10.1093/brain/awaf168}
}
EUVIMED